secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001140361-23-038715
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis Q2 2023 revenue up 40% to $188M; eplontersen PDUFA set for Dec 22, 2023
-----------------------------------------------------------------------------

- Total revenue $188M in Q2 (+40% YoY); operating loss $91M GAAP, $64M non-GAAP.
- Cash & short-term investments $2.4B; issued $575M notes due 2028 at 1.75%, repurchased $434M of 2024 notes.
- Eplontersen Phase 3 shows improvement through 85 weeks; PDUFA date Dec 22, 2023.
- Donidalorsen OASIS-HAE and eplontersen CARDIO-TTRansform enrollment complete; data H1:2024 and H1:2025.
- SPINRAZA royalties flat at $61M in Q2; Biogen's QALSODY approved for SOD1-ALS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036123038715/0001140361-23-038715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036123038715/brhc20057227_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-038715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer